Most reported cases of kidney injury on a GLP-1 follow dehydration from nausea, vomiting, or diarrhea. Rarer cases, such as acute interstitial nephritis (an inflammatory reaction in the kidney), don't run through dehydration. You can interrupt the dehydration chain at several points, and this guide shows how it develops and how to catch it early.
Overall, kidney risk isn't raised
Taking a GLP-1 does not appear to raise your baseline risk of kidney injury. A 2025 meta-analysis of 21 randomized trials covering 99,599 patients found GLP-1 use associated with a 9% reduction in acute kidney failure compared with placebo (Galli et al., JACC, 2025, DOI (external link)).
You may see a second study quoted alongside it. A 2025 real-world analysis matched 20,459 people with type 2 diabetes on a GLP-1 to 20,459 who weren't and reported lower rates of acute kidney injury (HR 0.54, 95% CI 0.49–0.60), sepsis, and shock among GLP-1 users (Nieto et al., American Journal of Gastroenterology, 2025, DOI (external link)). That study was built around acute pancreatitis, and kidney injury was counted as one of the complications of pancreatitis. It says GLP-1 users who were admitted with pancreatitis did better; it doesn't measure everyday kidney risk.
The risk that does exist is situational, and it mostly runs through dehydration.
How the risk develops
The Zepbound prescribing information lists "acute kidney injury due to volume depletion" as a warning. It notes postmarketing reports of acute kidney injury with GLP-1 medications, some needing dialysis, mostly in people who had nausea, vomiting, or diarrhea that led to dehydration, and it tells clinicians to monitor kidney function in those patients, especially when starting or raising the dose (DailyMed, Zepbound label, revised 8/2026 (external link)). An earlier review of GLP-1 side effects reached the same conclusion from case reports: kidney injury came mainly from fluid loss through GI symptoms (Filippatos et al., Review of Diabetic Studies, 2015, DOI (external link)).
A 2025 case report shows how it can happen. A patient who resumed semaglutide at a high dose without re-titrating developed severe nausea and vomiting, then dehydration, then acute kidney injury (Singhal et al., Cureus, 2025, DOI (external link)). One case shows the mechanism is real. It says nothing about how often it happens.
The chain
- Rapid dose escalation or an unusually strong individual response leads to significant nausea and/or vomiting.
- Vomiting and reduced fluid intake (often alongside eating less because of appetite suppression) lead to dehydration.
- Dehydration, if significant and prolonged, can reduce blood flow to the kidneys enough to cause injury.
You can break each link, which is where the practical advice below comes from.
If you already have kidney disease
This needs more care. A systematic review of semaglutide in diabetic kidney disease found albuminuria consistently reduced, which is a good sign, but variable effects on eGFR. It also flagged published cases of semaglutide-associated AKI, including acute interstitial nephritis. The authors recommended a personalised approach with vigilant monitoring, particularly in advanced chronic kidney disease (Rehman et al., Cureus, 2024, DOI (external link)). If you have existing kidney disease, talk this through with your prescriber specifically. Don't assume the reassuring population figures above apply unchanged to you.
How to reduce the risk
- Follow the recommended titration schedule. If you've missed doses and are restarting, raise it with your prescriber first. Restarting at a prior higher dose after a gap without re-titrating is exactly what happened in the case above; see how titration schedules work.
- Treat vomiting and significant nausea as a signal to actively manage hydration. Our guide on managing nausea has practical steps.
- Contact your prescriber if vomiting persists for more than a day or two, or if you can't keep fluids down at all. Don't wait to see if it resolves.
- Take extra care during illness. A stomach bug on top of GLP-1-related GI symptoms can dehydrate you quickly.
Signs dehydration may be getting significant
Reduced urination, dark urine, dizziness (especially when you stand up), a rapid heart rate, and fatigue beyond the usual titration tiredness all deserve prompt attention. Raise them with your prescriber. Lost fluid usually means lost salts too; see our guide on electrolytes on a GLP-1.
Pre-existing kidney disease calls for closer monitoring, not alarm. For most people, following the titration schedule and acting early on persistent vomiting are the two most effective protections.
Study findings above are attributed to their authors and were located via PubMed.
This article is for general education and is not medical advice. Talk with your prescriber or care team about your own situation. Persistent vomiting or inability to keep fluids down warrants prompt contact with your prescriber.